SNTI insider transaction filings
Senti Biosciences, Inc. — 37 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-03-11. Screen SNTI transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for SNTI between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Senti Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-11 | 4 | Lu Timothy K — CEO, Director | Tax withholding (F): 80,666 @ $0 | EDGAR |
| 2026-03-11 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Tax withholding (F): 10,757 @ $0 | EDGAR |
| 2026-02-03 | 4 | Lu Timothy K — CEO, Director | Tax withholding (F): 4,191 @ $0 | EDGAR |
| 2026-02-03 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Tax withholding (F): 1,384 @ $0 | EDGAR |
| 2025-07-21 | 4 | Baum Bryan Daniel — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Hsiung Feng — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Schulz Fran — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | COOPERSTONE BRENDA — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Tang Donald F — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Collins James J. — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Mathers Edward T — Director | Grant/award (A): 21,950 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Celadon Partners SPV 24 — 10% owner | Conversion (C): 9,777,000 · Conversion (C): 9,777 (derivative) | EDGAR |
| 2025-03-12 | 4 | New Enterprise Associates 15, L.P. — 10% owner NEA Partners 15, L.P. — 10% owner NEA 15 GP, LLC — 10% owner BASKETT FOREST — 10% owner Florence Anthony A. Jr. — 10% owner Makhzoumi Mohamad — 10% owner SANDELL SCOTT D — 10% owner | Conversion (C): 3,333,000 · Conversion (C): 3,333 (derivative) | EDGAR |
| 2025-03-12 | 4 | BAYER HEALTHCARE LLC — 10% owner Bayer US Holding LP — 10% owner Bayer World Investments B.V. — 10% owner BAYER AKTIENGESELLSCHAFT — 10% owner | Conversion (C): 2,222,000 · Conversion (C): 2,222 (derivative) | EDGAR |
| 2025-03-11 | 4 | Schulz Fran — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | COOPERSTONE BRENDA — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Hsiung Feng — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Tang Donald F — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Conversion (C): 33,000 @ $2.25 · Conversion (C): 33 (derivative) @ $2,250 | EDGAR |
| 2025-03-11 | 4 | Cross John Harry III — Chief Financial Officer | Grant/award (A): 174,200 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Collins James J. — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Mathers Edward T — Director | Grant/award (A): 43,900 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Lu Timothy K — CEO and Interim PFO and PAO, Director | Grant/award (A): 642,358 @ $0 · Grant/award (A): 1,927,073 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Grant/award (A): 78,363 @ $0 · Grant/award (A): 235,088 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Lu Timothy K — CEO, Director | Sale (S): 3,922 @ $4.07 · Sale (S): 545 @ $4.36 | EDGAR |
| 2025-02-06 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Sale (S): 1,297 @ $4.07 · Sale (S): 182 @ $4.37 | EDGAR |
| 2024-12-11 | 4 | BAYER HEALTHCARE LLC — 10% owner Bayer US Holding LP — 10% owner Bayer World Investments B.V. — 10% owner BAYER AKTIENGESELLSCHAFT — 10% owner | Purchase (P): 2,222 (derivative) · Purchase (P): 3,333,000 (derivative) | EDGAR |
| 2024-12-10 | 4 | Schulz Fran — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | Tang Donald F — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | Rajangam Kanya — Pres. & Chief Med. & Dev. Off. | Grant/award (A): 33 (derivative) @ $2,250 · Grant/award (A): 49,500 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | COOPERSTONE BRENDA — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | Collins James J. — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | Farokhzad Omid — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | Mathers Edward T — Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | KNOBELMAN DEBORAH — Chief Financial Officer | Grant/award (A): 101,000 @ $0 · Grant/award (A): 152,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Lu Timothy K — CEO and President, Director | Grant/award (A): 306,000 @ $0 · Grant/award (A): 459,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Rajangam Kanya — Chief Medical & Devt. Officer | Grant/award (A): 101,000 @ $0 · Grant/award (A): 152,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Senti Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2026-07-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 5.01 — Changes in Control of Registrant 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 5.01 — Changes in Control of Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SNTI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →